[en] Aim: To perform cross-sectional and longitudinal miRNA profiling in plasma from Duchenne muscular dystrophy (DMD) subjects and find non-invasive biomarkers in DMD. Subjects/materials & methods: Plasma was collected from 14 age and sex matched controls and 46 DMD subjects. Free-circulating and extracellular vesicle (EV)-derived miRNA expression was measured by RT-qPCR. Results: Free-circulating and EVs derived miR-29c-3p and miR-133a-3p are dysregulated in DMD subjects. Free-circulating and EV-derived miR-29c-3p are reduced in DMD subjects undergoing daily corticosteroid treatment. Free-circulating miR-1-3p and miR-122-5p are longitudinally upregulated in ambulant DMD subjects. Conclusion: We detected novel free-circulating and EV-derived dysregulated miRNAs in plasma from DMD subjects and characterized the longitudinal profile of free-circulating miRNA on plasma from DMD subjects.
Disciplines :
Pediatrics Neurology
Author, co-author :
Catapano, Francesco
Scaglioni, Dominic
Maresh, Kate
Ala, Pierpaolo
Domingos, Joana
Selby, Victoria
Ricotti, Valeria
Phillips, Lauren
Servais, Laurent ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur. J. Hum. Genet. 21(10), 1049-1053 (2013).
De Martinville B, Kunkel LM, Bruns G et al. Localization of DNA sequences in region Xp21 of the human X chromosome: search for molecular markers close to the Duchenne muscular dystrophy locus. Am. J. Hum. Genet. 37(2), 235-249 (1985).
Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl Acad. Sci. USA 90(8), 3710-3714 (1993).
Goemans N, Tulinius M, Kroksmark AK, Wilson R, Van Den Hauwe M, Campion G. Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids. Neuromusc. Disord. 27(3), 203-213 (2017).
Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane database Sys. Rev. doi: 10. 1002/14651858. CD003725. pub4 (5), CD003725 (2016).
Guiraud S, Davies KE. Pharmacological advances for treatment in Duchenne muscular dystrophy. Curr. Opin. Pharmacol. 34, 36-48 (2017).
Bladen CL, Salgado D, Monges S et al. The TREAT-NMD DMD Global Database: analysis of more than 7, 000 Duchenne muscular dystrophy mutations. Hum. Mutat. 36(4), 395-402 (2015).
Bushby K, Finkel R, Wong B et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50(4), 477-487 (2014).
Lim KR, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des. Dev. Ther. 11, 533-545 (2017).
Mah JK. An overview of recent therapeutics advances for Duchenne muscular dystrophy. Methods Mol. Biol. 1687, 3-17 (2018).
Zatz M, Shapiro LJ, Campion DS, Oda E, Kaback MM. Serum pyruvate-kinase (PK) and creatine-phosphokinase (CPK) in progressive muscular dystrophies. J. Neurol. Sci. 36(3), 349-362 (1978).
Goemans N, Mercuri E, Belousova E et al. A randomized placebo-controlled Phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Neuromusc. Disord. 28(1), 4-15 (2018).
Nelson CE, Wu Y, Gemberling MP et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat. Med. 25(3), 427-432 (2019).
Cherian AG, Hill JG. Age dependence of serum enzymatic activities (alkaline phosphatase, aspartate aminotransferase, and creatine kinase) in healthy children and adolescents. Am. J. Clin. Pathol. 70(5), 783-789 (1978).
Brewster LM, Mairuhu G, Bindraban NR, Koopmans RP, Clark JF, Van Montfrans GA. Creatine kinase activity is associated with blood pressure. Circulation 114(19), 2034-2039 (2006).
Coutts A, Reaburn P, Piva TJ, Murphy A. Changes in selected biochemical, muscular strength, power, and endurance measures during deliberate overreaching and tapering in rugby league players. Intl. J. Sports Med. 28(2), 116-124 (2007).
Nadarajah VD, Van Putten M, Chaouch A et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromusc. Disord. 21(8), 569-578 (2011).
Rouillon J, Poupiot J, Zocevic A et al. Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies. Human molecular genetics 24(17), 4916-4932 (2015).
Rouillon J, Zocevic A, Leger T et al. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy. Neuromusc. Disord. 24(7), 563-573 (2014).
Hathout Y, Brody E, Clemens PR et al. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. USA 112(23), 7153-7158 (2015).
Crescioli C, Sottili M, Bonini P et al. Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target. Eur. J. Cell Biol. 91(2), 139-149 (2012).
Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 113(6), 673-676 (2003).
Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 12(9), 735-739 (2002).
Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9(6), 654-659 (2007).
Weber JA, Baxter DH, Zhang S et al. The microRNA spectrum in 12 body fluids. Clin. Chem. 56(11), 1733-1741 (2010).
Cacchiarelli D, Legnini I, Martone J et al. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol. Med. 3(5), 258-265 (2011).
Catapano F, Zaharieva I, Scoto M et al. Altered levels of MicroRNA-9,-206, and-132 in spinal muscular atrophy and their response to antisense oligonucleotide therapy. Mol. Ther. Nucleic Acid 5(7), e331 (2016).
Zaharieva IT, Calissano M, Scoto M et al. Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular dystrophy. PloS one 8(11), e80263 (2013).
Mizuno H, Nakamura A, Aoki Y et al. Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. PloS one 6(3), e18388 (2011).
Townley-Tilson WH, Callis TE, Wang D. MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. Int. J. Biochem. Cell Biol. 42(8), 1252-1255 (2010).
Hu J, Kong M, Ye Y, Hong S, Cheng L, Jiang L. Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy. J. Neurochem. 129(5), 877-883 (2014).
Catapano F, Domingos J, Perry M et al. Downregulation of miRNA-29,-23 and-21 in urine of Duchenne muscular dystrophy patients. Epigenomics 10(7), 875-889 (2018).
Cheng L, Sharples RA, Scicluna BJ, Hill AF. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J. Extracell. Vesicles 3, (2014).
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4), 402-408 (2001).
D'haene B, Mestdagh P, Hellemans J, Vandesompele J. miRNA expression profiling: from reference genes to global mean normalization. Methods Mol. Biol. 822, 261-272 (2012).
Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 64(15), 5245-5250 (2004).
Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav. Brain. Res. 125(1-2), 279-284 (2001).
Chang KH, Mestdagh P, Vandesompele J, Kerin MJ, Miller N. MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer 10, 173 (2010).
Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat. Rev. Genet. 13(5), 358-369 (2012).
Hardikar AA, Farr RJ, Joglekar MV. Circulating microRNAs: understanding the limits for quantitative measurement by real-time PCR. J. Am. Heart Assoc. 3(1), e000792 (2014).
Li X, Li Y, Zhao L et al. Circulating Muscle-specific miRNAs in Duchenne muscular dystrophy patients. Mol. Ther. Nucleic Acids 3, e177 (2014).
Cacchiarelli D, Martone J, Girardi E et al. MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab. 12(4), 341-351 (2010).
Nguyen-Tran DH, Hait NC, Sperber H et al. Molecular mechanism of sphingosine-1-phosphate action in Duchenne muscular dystrophy. Dis. Mod. Mechan. 7(1), 41-54 (2014).
Deng Z, Chen JF, Wang DZ. Transgenic overexpression of miR-133a in skeletal muscle. BMC Musculoskel. Disord. 12, 115 (2011).
D'agostino M, Torcinaro A, Madaro L et al. Role of miR-200c in myogenic differentiation impairment via p66Shc: implication in skeletal muscle regeneration of Dystrophic mdx mice. Oxidat. Med. Cell. Longev. 2018, 4814696 (2018).
Eisenberg I, Eran A, Nishino I et al. Distinctive patterns of microRNA expression in primary muscular disorders. Proc. Natl. Acad. Sci. USA 104(43), 17016-17021 (2007).
Wang L, Zhou L, Jiang P et al. Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. Mol. Ther. J. Am. Soc. Gene Ther. 20(6), 1222-1233 (2012).
Zanotti S, Gibertini S, Curcio M et al. Opposing roles of miR-21 and miR-29 in the progression of fibrosis in Duchenne muscular dystrophy. BBA. 1852(7), 1451-1464 (2015).
Mccarthy JJ. The MyomiR network in skeletal muscle plasticity. Exerc. Sport Sci. Rev. 39(3), 150-154 (2011).
Liguori M, Nuzziello N, Introna A et al. Dysregulation of MicroRNAs and target genes networks in peripheral blood of patients with sporadic amyotrophic lateral sclerosis. Front. Mol. Neurosci. 11, 288 (2018).
Sun Y, Wang H, Li Y, Liu S, Chen J, Ying H. miR-24 and miR-122 negatively regulate the transforming growth factor-beta/smad signaling pathway in skeletal muscle fibrosis. Mol. Ther. Nucleic acids 11, 528-537 (2018).
Taguchi YH, Wang H. Exploring microRNA biomarker for amyotrophic lateral sclerosis. Intl. J. Mol. Sci. 19(5), 1318 (2018).
Takahashi I, Hama Y, Matsushima M et al. Identification of plasma microRNAs as a biomarker of sporadic amyotrophic lateral sclerosis. Mol. Brain 8(1), 67 (2015).
Zhou L, Wang L, Lu L, Jiang P, Sun H, Wang H. A novel target of microRNA-29, Ring1 and YY1-binding protein (Rybp), negatively regulates skeletal myogenesis. J. Biol. Chem. 287(30), 25255-25265 (2012).
Ricotti V, Selby V, Ridout D et al. Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: a prospective multicentre study. Neuromusc. Disord. 29(4), 261-268 (2019).
Seferian AM, Moraux A, Annoussamy M et al. Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial. PloS One 10(2), e0113999 (2015).
Chen JF, Mandel EM, Thomson JM et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 38(2), 228-233 (2006).
Chen JF, Tao Y, Li J et al. microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. J. Cell Biol. 190(5), 867-879 (2010).
Zhou L, Porter JD, Cheng G et al. Temporal and spatial mRNA expression patterns of TGF-beta1, 2, 3 and TbetaRI, II, III in skeletal muscles of mdx mice. Neuromusc. Disord. 16(1), 32-38 (2006).
Bernasconi P, Torchiana E, Confalonieri P et al. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J. Clin. Invest. 96(2), 1137-1144 (1995).
Zeng C, Wang YL, Xie C et al. Identification of a novel TGF-beta-miR-122-fibronectin 1/serum response factor signaling cascade and its implication in hepatic fibrogenesis. Oncotarget 6(14), 12224-12233 (2015).
Beaumont J, Lopez B, Hermida N et al. microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-beta1 up-regulation. Clin. Sci. (Lond) 126(7), 497-506 (2014).
Frankel KA, Rosser RJ. The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. Hum. Pathol. 7(4), 375-386 (1976).
